Can anybody provide some clarity for me, looking briefly at the operating cash flows and the cash outflows for the quarter ended 30 september 2020. The outflows are $1.8m and only set to increase seemingly for a long time during the phase 1 study set to begin in the "fourth calendar quarter"
even very conservatively a 2m cash burn per quarter and 8.3m in the bank, leaves a cash runway of just over a year before another capital raise is on the cards even after 2 capital raises in 2020.
Is this factor negligible in the valuation when compared to the potential upside of fast tracked FDA approval and the large addressable market for the product and potential up sells/expansion of the bussiness model?